What's in Janssen Vaccines & Prevention B.V.'s pipeline?

Janssen Vaccines & Prevention B.V. has 20 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 1 in Phase 2, 12 in Phase 1.

Which companies overlap with Janssen Vaccines & Prevention B.V.'s portfolio?

Top competitors by shared drug class: London School of Hygiene and Tropical Medicine, Seqirus, GlaxoSmithKline, Bharat Biotech International Limited, National Institute of Allergy and Infectious Diseases (NIAID).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/janssen-vaccines-prevention-b-v.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Janssen Vaccines & Prevention B.V. — Portfolio Competitive Intelligence Brief

Janssen Vaccines & Prevention B.V. pipeline: 0 marketed, 0 filed, 7 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 1 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
*Ad26.ZEBOV 210^10 (vp)**	Ad26.ZEBOV 2*10^10 (vp)	phase 3	Viral vector vaccine	Ebola virus glycoprotein (GP)	Immunology / Infectious Disease
Quadrivalent High-dose Influenza Vaccine	Quadrivalent High-dose Influenza Vaccine	phase 3	Influenza vaccine		Immunology
Ad26.RSV.preF-based vaccine	Ad26.RSV.preF-based vaccine	phase 3	Viral vector vaccine	RSV prefusion F protein	Immunology / Infectious Disease
Al(OH)3	Al(OH)3	phase 3	Vaccine adjuvant	NLRP3 inflammasome; antigen-presenting cells	Immunology
*MVA-BN-Filo 110^8 Infectious Unit [Inf. U.]**	MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]	phase 3	Recombinant viral vector vaccine	Filovirus glycoproteins (Ebola virus GP, Marburg virus GP)	Immunology / Infectious Disease
*MVA-BN-Filo 510^7 Inf. U.**	MVA-BN-Filo 5*10^7 Inf. U.	phase 3	Viral vector vaccine	Filovirus glycoproteins (Ebola virus GP, Marburg virus GP)	Immunology / Infectious Disease
*Ad26.ZEBOV 0.810^10 (vp)**	Ad26.ZEBOV 0.8*10^10 (vp)	phase 3	Viral vector vaccine	Ebola virus glycoprotein (GP)	Immunology / Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 5
Immunology · 2
Infectious Disease · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

London School of Hygiene and Tropical Medicine · 2 shared drug classes
Seqirus · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Bharat Biotech International Limited · 2 shared drug classes
National Institute of Allergy and Infectious Diseases (NIAID) · 2 shared drug classes
Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
CanSino Biologics Inc. · 2 shared drug classes
Boryung Pharmaceutical Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen Vaccines & Prevention B.V.:

Cite this brief

Drug Landscape (2026). Janssen Vaccines & Prevention B.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-vaccines-prevention-b-v. Accessed 2026-05-16.